Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Proteasome02:18

The Proteasome

8.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.5K
Proteins: From Genes to Degradation02:11

Proteins: From Genes to Degradation

3.5K
3.5K
Amino Acid Catabolism01:18

Amino Acid Catabolism

1
Microorganisms rely on proteins as an essential carbon and energy source, particularly in environments with limited polysaccharides or lipids. However, proteins are too large to cross the plasma membrane unaided, necessitating enzymatic degradation. Microbes secrete extracellular proteases and peptidases that hydrolyze proteins into peptides, which can then be transported across the membrane. Once inside the cell, intracellular proteases degrade these peptides into free amino acids, which...
1
Regulated Protein Degradation02:58

Regulated Protein Degradation

2.5K
2.5K
The Proteasome Structure01:17

The Proteasome Structure

697
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
697
Protein Digestion01:02

Protein Digestion

102.6K
Protein digestion begins in the stomach, where the highly acidic environment can easily disrupt protein structure by exposing the peptide bonds of polypeptide chains. After polypeptide chains are broken into individual amino acids by a series of digestive enzymes, the amino acids are transported to the liver via the bloodstream to produce energy.
102.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unraveling Metabolic Syndrome: Dr Pories Does It Again.

Journal of the American College of Surgeons·2026
Same author

Safety considerations for cereblon-recruiting targeted protein degraders.

Nature reviews. Drug discovery·2026
Same author

Optimizing Safety and Outcomes in Metabolic/Bariatric Surgery: A Conceptual Framework for Staged Minimally Invasive Treatment.

Obesity surgery·2026
Same author

Toxicologic Pathology Forum*: Summary of the 2024 Society of Toxicologic Pathology Town Hall and 2025 STP Member Survey on Determining and Communicating Adversity.

Toxicologic pathology·2025
Same author

Early experience of simultaneous sleeve gastrectomy in living donor liver transplant recipients with obesity - a pilot study.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery·2025
Same author

STP Town Hall Discussion on the Use of Virtual Control Groups in Nonclinical Toxicity Studies.

Toxicologic pathology·2025
Same journal

New Approach Methodologies (NAMs) for Carcinogenicity Evaluation.

Toxicologic pathology·2026
Same journal

2025 International Academy of Toxicologic Pathology (IATP) Satellite Symposium: Pathology Working Groups (PWGs) in Toxicologic Pathology.

Toxicologic pathology·2026
Same journal

Toxicologic Pathology Forum*: Opportunities and Challenges in the Use of Artificial Intelligence in Nonclinical Toxicologic Histopathology Evaluations.

Toxicologic pathology·2026
Same journal

New Modalities and Carcinogenicity Assessment.

Toxicologic pathology·2026
Same journal

Second Joint Annual Congress of the British Society of Toxicologic Pathology and the European Society of Toxicologic Pathology Special Issue.

Toxicologic pathology·2026
Same journal

Hemangiosarcomas in Intercostal Brown Adipose Tissues of the Sternum Induced by Urethane in TgrasH2 Mice.

Toxicologic pathology·2026
See all related articles

Related Experiment Video

Updated: Jun 5, 2025

Tuning Degradation to Achieve Specific and Efficient Protein Depletion
05:11

Tuning Degradation to Achieve Specific and Efficient Protein Depletion

Published on: July 20, 2019

6.2K

Session 5: Protein Degraders.

Kiran Palyada1, Renee Hukkanen2, Stephanie Leuenroth-Quinn3

  • 1Pfizer Inc., La Jolla, California, USA.

Toxicologic Pathology
|December 11, 2024
PubMed
Summary
This summary is machine-generated.

Targeted protein degradation (TPD) offers a new approach to developing drugs for previously undruggable proteins by utilizing the cell's natural degradation pathways. This session explored TPD's challenges, toxicities, and development considerations.

Keywords:
E3 ligasePROTACVHLcereblonheterobifunctional moleculesmolecular gluesprotein degraders

More Related Videos

Reporter-based Growth Assay for Systematic Analysis of Protein Degradation
07:47

Reporter-based Growth Assay for Systematic Analysis of Protein Degradation

Published on: November 6, 2014

10.7K
Assaying Proteasomal Degradation in a Cell-free System in Plants
07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

14.4K

Related Experiment Videos

Last Updated: Jun 5, 2025

Tuning Degradation to Achieve Specific and Efficient Protein Depletion
05:11

Tuning Degradation to Achieve Specific and Efficient Protein Depletion

Published on: July 20, 2019

6.2K
Reporter-based Growth Assay for Systematic Analysis of Protein Degradation
07:47

Reporter-based Growth Assay for Systematic Analysis of Protein Degradation

Published on: November 6, 2014

10.7K
Assaying Proteasomal Degradation in a Cell-free System in Plants
07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

14.4K

Area of Science:

  • Drug Development
  • Biochemistry
  • Pharmacology

Background:

  • The
  • undruggable
  • proteome presents a significant challenge in drug discovery.
  • Targeted protein degradation (TPD) has emerged as a promising therapeutic modality to address this challenge.
  • TPD leverages the cell's endogenous ubiquitin-proteasome system for targeted protein elimination.

Purpose of the Study:

  • To explore the challenges and perspectives of utilizing protein degraders as novel therapeutic agents.
  • To discuss the evaluation of on- and off-target toxicities associated with TPD.
  • To present unique considerations for the development and safety assessment of degrader molecules.

Main Methods:

  • Review of current TPD strategies and their application in drug development.
  • Analysis of on- and off-target toxicities through an IQ Consortium working group survey.
  • Presentation of unique absorption, distribution, metabolism, and excretion (ADME) properties of degrader molecules.
  • Discussion on the use of transgenic models for evaluating hemotoxicity.
  • Case study illustrating the derisking of dose-limiting thrombocytopenia.
  • Inclusion of a regulatory perspective on TPD-associated toxicities.

Main Results:

  • TPD modalities are transitioning from academia to industry, offering new therapeutic avenues.
  • Specific ADME properties of degrader molecules impact drug development and nonclinical safety.
  • Hemotoxicity, particularly thrombocytopenia, is a key safety concern requiring careful evaluation.
  • Transgenic models and case studies provide valuable insights into managing TPD-related toxicities.

Conclusions:

  • Protein degraders represent a significant advancement in targeting previously undruggable proteins.
  • Addressing unique ADME properties and potential toxicities, such as hemotoxicity, is crucial for successful TPD development.
  • A multidisciplinary approach, including regulatory considerations, is essential for advancing TPD therapies.